Lupin Limited
http://www.lupin.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lupin Limited
First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle
Canadian firm received approval from FDA for NDA submitted in May 2023 for Lumify Preservative Free. A month earlier, FDA approved Dr. Reddy's ANDA submitted in July 2021 for an equivalent of Lumify’s formulation, brimonidine tartrate 0.025% ophthalmic solution.
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.
US Court Provides Opportunity For Lupin And Zydus To Debut Generic Myrbetriq
Lupin and Zydus are targeting a market worth at least $1bn a year – and more than $2.4bn all told – after both in quick succession announcing the launch of generic versions of Astellas Pharma’s Myrbetriq treatment for overactive bladder.
Lupin Bags First US Rival To $1.6bn Ingrezza – But Launch Will Have To Wait
Lupin has claimed the first US approval for an Ingrezza generic – but must wait well over a decade before launching its version of valbenazine, after last year striking a patent litigation settlement with originator Neurocrine Biosciences.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Generic Health Pty Ltd
- Temmler Pharma GmbH & Co.
- YL Biologics (YLB)
- ZAO Biocom
- Kyowa Pharmaceutical Industry Co., Ltd.
- Southern Cross Pharma Pty Ltd
- Symbiomix Therapeutics, LLC.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice